Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Mayo Clinic National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00655655 |
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.
Condition | Intervention | Phase |
---|---|---|
Gastrointestinal Carcinoid Tumor Head and Neck Cancer Islet Cell Tumor Kidney Cancer Lung Cancer Melanoma (Skin) Neuroendocrine Carcinoma of the Skin Pheochromocytoma Unspecified Adult Solid Tumor, Protocol Specific |
Drug: everolimus Drug: vatalanib Procedure: dynamic contrast-enhanced magnetic resonance imaging Procedure: high performance liquid chromatography Procedure: immunohistochemistry staining method Procedure: laboratory biomarker analysis Procedure: mass spectrometry Procedure: pharmacological study Procedure: protein expression analysis Procedure: ultrasound imaging |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors |
Estimated Enrollment: | 96 |
Study Start Date: | December 2004 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed solid tumor
PATIENT CHARACTERISTICS:
No concurrent, severe and/or uncontrolled medical condition that would compromise study participation or pose as unnecessary risk to the patient, including, but not limited, any of the following:
No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of vatalanib, including any of the following:
PRIOR CONCURRENT THERAPY:
More than 4 weeks since prior full-field radiotherapy
More than 2 weeks since prior limited-field radiotherapy
United States, Minnesota | |
Mayo Clinic Cancer Center | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Clinical Trials Office - All Mayo Clinic Locations 507-538-7623 |
Study Chair: | Julian Molina, MD, PhD | Mayo Clinic |
Study ID Numbers: | CDR0000592921, MAYO-MC0414 |
Study First Received: | April 9, 2008 |
Last Updated: | December 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00655655 |
Health Authority: | Unspecified |
unspecified adult solid tumor, protocol specific stage IV renal cell cancer recurrent renal cell cancer stage IV melanoma recurrent melanoma stage IV non-small cell lung cancer recurrent non-small cell lung cancer metastatic gastrointestinal carcinoid tumor recurrent gastrointestinal carcinoid tumor gastrinoma |
glucagonoma insulinoma recurrent islet cell carcinoma pancreatic polypeptide tumor somatostatinoma recurrent neuroendocrine carcinoma of the skin thyroid gland medullary carcinoma metastatic pheochromocytoma recurrent pheochromocytoma stage III neuroendocrine carcinoma of the skin |
Thoracic Neoplasms Carcinoma, Basosquamous Pancreatic Neoplasms Pancreatic Polypeptide Urogenital Neoplasms Urologic Neoplasms Vatalanib Lung Neoplasms Neuroepithelioma Kidney Diseases Endocrine Gland Neoplasms Non-small cell lung cancer Digestive System Neoplasms Carcinoma, Islet Cell Insulinoma |
Endocrine System Diseases Carcinoma, Basal Cell Adenoma, Islet Cell Renal cancer Malignant Carcinoid Syndrome Carcinoma Carcinoma, Merkel Cell Neuroectodermal Tumors Gastrinoma Lung Diseases Gastrointestinal Neoplasms Pancreatic Diseases Carcinoid Tumor Nevus Carcinoma, Squamous Cell |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immunologic Factors Neoplasms, Nerve Tissue Physiological Effects of Drugs Enzyme Inhibitors |
Immunosuppressive Agents Protein Kinase Inhibitors Pharmacologic Actions Neoplasms Neoplasms by Site Neoplasms, Basal Cell Nevi and Melanomas |